

FIG. 1


Recombinant human ST2 Tolerance
Percent Recovery
100
75
50
25
0
0
20
40
60
80
100
Concentration rhST2 (ng/mL)
C-AD Acid Treated
C-AD No Acid
C-A-D Acid Treated
C-A-D No Acid

FIG. 2A


2,500
2,000
1,500
1,000
500
0
Counts
Individual 1
Individual 2
Individual 3
C-A-D
No Acid
C-AD
No Acid
C-A-D
Acid
C-AD
Acid

FIG. 2b


Endogenous IL-33 Specificity
2,500
2,000
1,500
1,000
500
0
Counts
Modified Assay
Addition of rST2
Addition of Anti-IL-33
88% Inhibition
97% Inhibition
Individual 1
Individual 3

FIG. 3


250
200
150
100
50
0
IL-33 Concentration (pg/mL)
Individual 1
Individual 3

FIG. 4


Anti-IL-33 Tolerance
Percent Recovery
100
75
50
25
0
0
200
400
600
800
1000
Concentration anti-IL-33 (µg/mL)
C-AD Acid Treated
C-A-D Acid Treated

FIG. 5


Levels of IL-33 in Diseased Individuals
Endogenous IL33 Levels (pg/mL)
40
30
20
LLOQ
10
0
NHS
Asthma
COPD
Atopic Dermatitis
Mean (pg/mL): 15.3 11.5 15.4 16.2
Stand Dev: 5.73 4.37 4.55 5.02

FIG.6


Human IL-33 (pg/mL)
300
200
100
0
Saline Control
HDM Control
Isotype Control
Anti-IL-33

FIG.7A


Human IL-33 (pg/mL)
300
200
100
0
Saline Control
HDM Control
Isotype Control
Anti-IL-33

FIG.7B